Splitting a weekly tirzepatide dose means injecting half of it twice a week, usually 3 or 4 days apart. The practice appears on clinic blogs and forums, often as a way to soften side effects. This page sets out what the label says, what a registry search finds, what the half-life arithmetic does to blood levels, and the syringe readings for each half. Medibact's Tirzepatide guide covers the molecule; the tirzepatide dosage page reports the full label schedule.
What the label and the registry hold
The ZEPBOUND label read on 2026-09-27 (revision ZEP-0016-USPI-20260828) is written for one injection a week at every step:
| Label element | What it states |
|---|---|
| Starting dose | 2.5 mg once weekly for 4 weeks; "not approved as a maintenance dosage" |
| Escalation | 2.5 mg increments, at least 4 weeks apart |
| Maintenance | 5, 10 or 15 mg once weekly (weight); 10 or 15 mg (sleep apnoea) |
| Maximum | 15 mg once weekly |
| Missed dose | give within 4 days (96 hours), otherwise skip |
| Changing the day | at least 3 days (72 hours) between two doses |
The label contains the word "twice" only in its animal studies, where pregnant rats were dosed twice weekly. A ClinicalTrials.gov search for "tirzepatide twice weekly" returned five records on the same date; in each one "twice" describes something else — twice-daily nerve stimulation, twice-daily metformin, twice-daily azelaprag beside weekly tirzepatide. The one registered trial moving in the opposite direction, NCT07832084 (not yet recruiting), steps people down from 15 mg weekly to 5 mg every other week to test weight maintenance.
What splitting does to blood levels
The label gives the numbers a model needs: peak at a median 24 hours after injection (range 8 to 72), 80% bioavailability, half-life of about 5 to 6 days, steady state after 4 weeks. A one-compartment model with instant absorption, which overstates every swing, gives these steady-state figures for the same weekly total, as multiples of one weekly dose:
| Half-life used | Schedule | Peak | Trough | Peak ÷ trough |
|---|---|---|---|---|
| 5 days | once weekly | 1.61 | 0.61 | 2.64 |
| 5 days | half dose twice weekly | 1.30 | 0.80 | 1.62 |
| 6 days | once weekly | 1.80 | 0.80 | 2.24 |
| 6 days | half dose twice weekly | 1.50 | 1.00 | 1.50 |
So at steady state the peak is about 17–19% lower and the trough about 25–31% higher; the average level between doses is identical, because the same milligrams go in each week. The difference is largest in the first week: before accumulation, a half dose peaks at half the height of a whole one, and 3.5 days later about 62% of it is still present when the second half goes in.
Pages on splitting quote larger figures. One, updated 2026-09-05, states that twice-weekly dosing lowers the peak by "30 to 40 percent". That range sits between the first-week figure (50%) and the steady-state figure above, and none of these numbers has been measured in people on split tirzepatide; they are arithmetic on a label half-life. The tirzepatide half-life page works through the accumulation week by week, and the dosing frequency page sets tirzepatide beside compounds with much shorter half-lives.
Whether a flatter curve means fewer side effects has not been tested. The label's own tool for gastrointestinal symptoms is slower escalation — at least 4 weeks per step — not a change of frequency.
Which presentations can be split
| Presentation | How the dose is set | Can a half be drawn? |
|---|---|---|
| Single-dose pen (2.5–15 mg in 0.5 mL) | whole contents, one press | no |
| KwikPen (4 fixed doses) | fixed dose per click-through | no half setting |
| Single-dose vial (2.5–15 mg in 0.5 mL) | syringe | physically yes; the label directs the whole vial once |
| Multi-dose vial (4 doses in 2.4 mL) | syringe, 0.6 mL per dose | physically yes; label counts 4 weekly doses |
| Research vial (powder, 10/15/30 mg) | reconstituted, syringe | depends on the water added |
The multi-dose vial's label adds a limit that splitting runs into: it is discarded 30 days after first use or after 4 weekly doses, "even if it still has medicine in it". Eight half-doses over four weeks stay inside that limit; stretching the vial further does not.
Units for each half
Units on a U-100 syringe = mg ÷ mg/mL × 100. The multi-dose vial strengths are 4.17 mg/mL (2.5 mg), 8.33 (5 mg), 12.5 (7.5 mg) and upward, so every whole dose is 60 units and every half is 30 units, whatever the strength. For research vials the reading moves with the water:
| Weekly amount | Half | 5 mg/mL (10 mg + 2 mL) | 10 mg/mL (10 mg + 1 mL) | 15 mg/mL (30 mg + 2 mL) | 30 mg/mL (30 mg + 1 mL) |
|---|---|---|---|---|---|
| 2.5 mg | 1.25 mg | 25 | 12.5 | 8.3 | 4.2 |
| 5 mg | 2.5 mg | 50 | 25 | 16.7 | 8.3 |
| 7.5 mg | 3.75 mg | 75 | 37.5 | 25 | 12.5 |
| 10 mg | 5 mg | 100 | 50 | 33.3 | 16.7 |
| 12.5 mg | 6.25 mg | 125 | 62.5 | 41.7 | 20.8 |
| 15 mg | 7.5 mg | 150 | 75 | 50 | 25 |
Figures above 100 do not fit one 1 mL syringe; readings with a decimal fall between the 1-unit marks. Halving a dose halves the reading, so the concentrated vials push the smallest halves below 10 units, where a 1-unit error is more than 10% of the amount. The mg to units page sets out the formula, the tirzepatide reconstitution page the water volumes, and the calculator works any vial.
What is not established
No trial has compared twice-weekly with once-weekly tirzepatide for weight, glucose or side effects. The level figures on this page come from a model built on the label's half-life, not from measurements in people splitting doses. Whether research-market tirzepatide matches Lilly's molecule is not known. Nothing on this page is a dose, a schedule or a suggestion to change one.
Sources and dates
Opened 2026-09-27: the ZEPBOUND label (Eli Lilly, DailyMed set id 487cd7e7-434c-4925-99fa-aa80b1cc776b, revision ZEP-0016-USPI-20260828) sections 2, 3, 8.1, 11, 12.3 and 16; the MOUNJARO listing on DailyMed (set id d2d7da5d); ClinicalTrials.gov v2 searches for "tirzepatide twice weekly", "tirzepatide split dose" and "tirzepatide daily" with tirzepatide as the intervention, and the arm descriptions or summaries of NCT07619989, NCT07635953, NCT06515418, NCT06861439, NCT07303556, NCT07457437 and NCT07832084; a PubMed search for tirzepatide with twice-weekly, split or divided dosing (four records, none a split-dose study); two consumer pages on splitting (dated 2026-06-15 and 2026-09-05), quoted for what they state. The model, its ratios and the unit figures are arithmetic by this site. Corrections go to the contact page.